A review of Tumor Treating Fields and their future implication in treatment of platinum resistant ovarian cancer

Ovarian cancer is a leading cause of morbidity and mortality amongst gynecologic malignancies. Due to the lack of screening tests and early detection, most cases of ovarian cancer are diagnosed in advanced stages. Treatment of patients includes multidisciplinary approaches that include surgical debulking and chemoradiation therapy. Recently, there have been emerging clinical trials that are investigating the use of Tumor treating fields (TTFields) in the treatment of patients with ovarian cancer. Tumor treating fields (TTFields) are a novel, non-invasive cancer treatment modality targeted towards inhibition of solid tumor growth.1,2 The use of TTFields was initially approved by the US Food and Drug Administration (FDA) for treatment of recurrent glioblastoma multiforme. In this article, we will be providing an overview of TTFields, including its mechanism of action, burgeoning application in the management of solid tumors, and promising potential in the treatment of patients with platinum resistant ovarian cancer.